Trial Profile

A retrospective study of pharmacokinetic interactions of letermovir in lung transplant recipients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letermovir (Primary)
Indications Transplant rejection
Focus Pharmacokinetics

Most Recent Events

10 Jun 2022 New trial record
30 Apr 2022 Primary endpoint (Dose-adjusted immunosuppression troughs (concentration/dose or C/D ratios)) has not been met, according to Results presented at the 42nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
30 Apr 2022 Results presented at the 42nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com